etoposide + ifosfamide + doxorubicin

EIA is a combination chemotherapy regimen consisting of etoposide, ifosfamide, and doxorubicin (adriamycin), developed by Heidelberg University for the treatment of high-risk soft tissue sarcoma. The regimen is typically administered in a neoadjuvant and adjuvant setting alongside surgery and radiotherapy, as investigated in the Phase II NeoWTS trial (NCT01382030). Its mechanism of action involves the synergistic effects of three cytotoxic agents: ifosfamide, an alkylating agent that cross-links DNA; doxorubicin, an anthracycline that intercalates into DNA and inhibits topoisomerase II; and etoposide, a podophyllotoxin derivative that also targets topoisomerase II to induce double-stranded DNA breaks. This intensive protocol is designed to provide both local and systemic control for patients with high-risk features such as large tumor size and high histological grade.

Other names

EIA regimenEIA chemotherapyEIA-Heidelberg University-soft tissue sarcomaetoposide + ifosfamide + adriamycin